Achillion Pharmaceuticals 10-Q2017 Q3 Quarterly report

Content analysis

Filed: 1 Nov 17, 12:00am

Dated: November 1, 2017

/s/ MARY KAY FENTON

Mary Kay Fenton

Chief Financial Officer

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Avner, bill, biopsy, Bioverativ, bipartisan, chamber, characteristic, codified, companion, Comparison, congressional, CSR, dysregulation, eGFR, eleven, endpoint, faith, FDARA, filtration, function, glomerular, house, Ingerman, introduced, JNJ, lampalizumab, mediated, passed, precedent, proteinuria, put, randomized, Reauthorization, renal, Senate, sentinel, session, sham, skinny, software, stay, taper, unambiguously, undermine, unilateral, unilaterally, wind

Removed: abated, AbbVie, achieved, Affordability, antiviral, approvability, assured, ASU, atrioventricular, attempt, attributed, attribution, billion, block, cessation, closing, cohort, commensurate, consisted, contemplated, contemplation, cure, cured, deciding, defense, diligence, discernable, earn, ECG, echocardiographic, echocardiography, Enanta, enhancement, enrolled, exist, formed, genotype, Gilead, headache, heighten, IIa, IIb, importation, infected, insolvency, jointly, JSC, litigated, Merck, method, mild, Mobitz, mutual, North, Olysio, ophthalmic, participant, pattern, pertaining, premature, prosecute, prosecuted, prosecution, QD, QOD, relate, represent, respiratory, revert, simeprevir, standalone, steering, subsidiary, sustained, tract, triple, True, uncured, undisputed, unit, upfront, upper, validated, viewed, vote, waiting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Achillion Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form10-Q of Achillion Pharmaceuticals, Inc. (the “Company”) for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mary Kay Fenton, Chief Financial Officer of the Company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to her knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.